Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation

M. Ibrahim-Kosta, P. Suchon, F. Couturaud, D. Smadja, R. Olaso, M. Germain, N. Saut, L. Goumidi, C. Derbois, F. Thibord, S. Debette, P. Amouyel, J. F. Deleuze, P. van Doorn, E. Castoldi, E. Patin, M. C. Alessi, D. A. Tregouet, P. E. Morange*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)


Factor V serves an important role in the regulation of blood coagulation. The rs6025 (R534Q) and rs4524 (K858R) polymorphisms in the F5 gene, are known to influence the risk of venous thrombosis. While the rare Q534 (factor V Leiden) allele is associated with an increased risk of venous thrombosis, the minor R858 allele is associated with a lower risk of disease. However, no study has deeply examined the cumulative impact of these two variations on venous thrombosis risk. We study the association of these polymorphisms with the risk of venous thrombosis in 4 French case-control populations comprising 3719 patients and 4086 controls. We demonstrate that the Q534 allele has a dominant effect over R858. Besides, we show that in individuals not carrying the Q534 allele, the protective effect of the R858 allele acts in a dominant mode. Thrombin generation-based normalized activated protein C sensitivity ratio was lower in the 858R/R homozygotes than in the 858K/K homozygotes (1.92 +/- 1.61 vs 2.81 +/- 1.57, p= 0.025). We demonstrate that the R858 allele of the F5 rs4524 variant protects from venous thrombosis only in non-carriers of the Q534 allele of the F5 rs6025. Its protective effect is mediated by reduced factor VIII levels and reduced activated protein C resistance.

Original languageEnglish
Article number3750
Number of pages7
JournalScientific Reports
Publication statusPublished - 6 Mar 2019


  • GENE
  • RISK

Cite this